References:

1. Narayanan, R., Coss, C., Dalton, J. (2018). Development Of Selective Androgen Receptor Modulators (Sarms). Molecular and Cellular Endocrinology, (465), 134-142.
2. Dodson, S., Baracos, V., Jatoi, A., Evans, W., Cella, D., Dalton, J., … & Steiner, M. (2011). Muscle Wasting In Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies. Annu. Rev. Med., 1(62), 265-279.
3. Solomon, Z., Mirabal, J., Mazur, D., Kohn, T., Lipshultz, L., Pastuszak, A. (2019). Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sexual Medicine Reviews, 1(7), 84-94.
4. Bhasin, S., Jasuja, R. (2009). Selective Androgen Receptor Modulators As Function Promoting Therapies. Current Opinion in Clinical Nutrition and Metabolic Care, 3(12), 232-240.
5. Dalton, J., Barnette, K., Bohl, C., Hancock, M., Rodriguez, D., Dodson, S., … & Steiner, M. (2011). The Selective Androgen Receptor Modulator Gtx‐024 (Enobosarm) Improves Lean Body Mass and Physical Function In Healthy Elderly Men And Postmenopausal Women: Results Of A Double‐blind, Placebo‐controlled Phase II Trial. J cachexia sarcopenia muscle, 3(2), 153-161.
6. Mohler, M., Bohl, C., Jones, A., Coss, C., Narayanan, R., He, Y., … & Miller, D. (2009). Nonsteroidal Selective Androgen Receptor Modulators (Sarms): Dissociating the Anabolic And Androgenic Activities Of The Androgen Receptor For Therapeutic Benefit. J. Med. Chem., 12(52), 3597-3617.
7. Panneerselvam, P., Singh, L., Selvarajan, V., Chng, W., Ng, S., Tan, N., … & Ding, J. (2012). T-cell Death Following Immune Activation Is Mediated By Mitochondria-localized Sarm. Cell Death Differ, 3(20), 478-489.
8. Peng, J., Yuan, Q., Lin, B., Panneerselvam, P., Wang, X., Luan, X., … & Ding, J. (2010). Sarm Inhibits Both Trif- and Myd88-mediated Ap-1 Activation. Eur. J. Immunol., 6(40), 1738-1747.
9. Yin, D., Gao, W., Kearbey, J., Xu, H., Chung, K., He, Y., … & Dalton, J. (2002). Pharmacodynamics Of Selective Androgen Receptor Modulators. J Pharmacol Exp Ther, 3(304), 1334-1340.